PAVmed Plans Business Update Call to Highlight Growth Strategies
Upcoming conference call and webcast scheduled for 8:30 AM Eastern Time.
PAVmed Inc. (NASDAQ: PAVM), a leading diversified medical technology company, has announced an important business update conference call. This event will take place at 8:30 AM Eastern Time. The discussion will cover critical insights about the company’s operations and future growth strategies, providing investors and stakeholders with valuable information.
Company Leadership Presentation
During the call, Dr. Lishan Aklog, M.D., Chairman and CEO of PAVmed, will lead the presentation. He will share a comprehensive overview of the company’s operations, shedding light on recent developments and strategic initiatives aimed at fostering growth and success within the medical device, diagnostics, and digital health sectors.
Financial Insights from Key Executives
Additionally, Dennis McGrath, the company’s President and CFO, will provide an update on the third quarter financial results. His insights will be crucial for understanding the company’s current position and future outlook.
Webcast Accessibility
The conference call will be accessible via a webcast on the investor relations section of the PAVmed website. Interested parties are encouraged to join by dialling the designated telephone lines, with U.S. callers dialing 1-800-836-8184 and international participants calling 1-646-357-8785. Participants should refer to the call name "PAVmed Business Update" when prompted by the operator.
Replay Availability
For those who cannot attend the live session, a replay will be made available for 30 days after the conclusion of the call. This will also be hosted in the investor relations section of PAVmed’s official site.
About PAVmed Inc.
PAVmed Inc. is a dynamic commercial-stage medical technology firm specializing in the development of innovative medical devices, diagnostics, and digital health solutions. One of its notable subsidiaries, Lucid Diagnostics (NASDAQ: LUCD), is at the forefront of cancer prevention. It offers the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device, both designed for early detection of esophageal precancer. These pioneering tools play a crucial role in mitigating risks associated with esophageal cancer.
Innovations in Personalized Cancer Care
PAVmed's other subsidiary, Veris Health Inc., is dedicated to enhancing personalized care in cancer management. It focuses on remote patient monitoring through advanced biologic sensors and a suite of external devices. Veris is also in the process of developing an implantable physiological monitor to work alongside chemotherapy ports, further advancing cancer care technology.
For more comprehensive information about the offerings and innovations of PAVmed, visit their official website.
Frequently Asked Questions
What is the date and time of the upcoming conference call?
The conference call is scheduled for November 14, 2024, at 8:30 AM Eastern Time.
Who will be presenting in the conference call?
Dr. Lishan Aklog, M.D., the Chairman and CEO, along with Dennis McGrath, President and CFO, will present key insights.
How can I access the conference call?
Participants can join by web or telephone, with specific numbers provided for U.S. and international callers.
Is there a replay available for the call?
Yes, a replay will be accessible for 30 days following the call.
What are PAVmed's main areas of operation?
PAVmed is involved in medical devices, diagnostics, and digital health sectors, aiming to innovate and improve patient outcomes.
